HeLa

HeLa (Cervical Cancer CDX Model) 

The HeLa cell line was established from cervical carcinoma of a 31-year-old female patient in 1951. It is the first immortalized human cell line and remains one of the most widely used models in biomedical research. HeLa has contributed to countless discoveries in cancer biology and therapeutics. Its robustness ensures consistent use across oncology pipelines. 

Key Features: 

• Derived from cervical carcinoma. 

• First immortalized human cell line. 

• Highly proliferative and adaptable. 

• Tumorigenic in xenograft systems. 

Applications: 
HeLa is applied in cervical cancer drug testing and biomarker research. It supports broad oncology research beyond its original tumor type due to its robust growth. Researchers use it to evaluate therapeutic efficacy, mechanisms of carcinogenesis, and viral oncology. It is a cornerstone in preclinical development.